Installation of cleanroom PODs at J.POD Toulouse, France (EU)
Evotec SE today announced the successful arrival and start of installation of the cleanroom PODs at its J.POD biologics manufacturing facility located on Evotec’s Campus Curie in Toulouse, France....
View ArticleEvotec SE Annual General Meeting 2023 approves all proposed agenda items
Evotec SE today announced that its shareholders approved all proposals the Company’s Management put to vote at the Company’s virtual Annual General Meeting 2023 with the required majority.
View ArticleEvotec receives milestone payment for first patient dosed in Phase I …
Evotec SE announced today that it is to receive a € 2 m milestone payment from Bayer AG, which is triggered by the first patient dosed in the clinical Phase I study of a kidney disease programme...
View ArticleJust – Evotec Biologics awarded second contract from U.S. Department of …
Evotec SE today announced that the U.S. Department of Defense (“DOD”) has awarded Evotec’s Seattle-based subsidiary, Just – Evotec Biologics, Inc. a contract valued up to $ 74 m for the rapid...
View ArticleEvotec and Bristol Myers Squibb enter licence agreement within …
Evotec SE today announced that Bristol Myers Squibb Company has exercised its option to enter into an exclusive global licence agreement. The licence covers selected late-stage discovery programmes...
View ArticleEvotec provides update on financial impact of cyber-attack
Evotec SE today announced that it is adjusting its guidance for the fiscal year 2023 due to the impact of the cyber-attack.
View ArticleAd hoc: Evotec provides update on financial impact of cyber-attack
Evotec SE announces that it is adjusting its guidance for the fiscal year 2023.
View ArticleEvotec-partner STORM Therapeutics to present the discovery of lead …
Evotec today announced that its partner STORM Therapeutics Ltd. (“STORM”), a clinical stage biotechnology company focused on discovering and developing novel small molecule therapies targeting RNA...
View ArticleEvotec SE reports first half-year 2023 results on 29 August 2023
Evotec SE will announce its financial results for the first half-year of 2023 on Tuesday, 29 August 2023.
View ArticleEvotec SE reports results for the first half-year 2023 and provides …
Evotec SE today announced its financial results and corporate updates for the first half-year of 2023.
View ArticleEvotec and Novo Nordisk launch LAB eN² to accelerate translation in ...
Evotec SE and Novo Nordisk today announced LAB eN² (pronounced Lab ee – en – squared), a translational drug discovery accelerator that aims to nurture early research from academic institutions into...
View ArticleEvotec SE: Launch of partnering agreement to strengthen biotech ...
Evotec SE, LabCentral, a launchpad for high-potential life science and biotech start-ups, BioLabs, an international membership based network of shared lab and office facilities, and MBC BioLabs,...
View ArticleEvotec opens new state-of-the-art biology facility on Dorothy Crowfoot ...
Evotec SE today celebrated the Grand Opening of a new facility, Building 95 (“B95”), on the Company’s Dorothy Crowfoot Hodgkin Campus at Milton Park. Evotec has had a presence in Abingdon since the...
View ArticleEvotec, ClavystBio, Leaps by Bayer, Lightstone Ventures and Polaris...
Evotec SE today announced that the Company has entered into a new BRIDGE partnership with Lightstone Ventures, ClavystBio, Leaps by Bayer, Polaris Partners, and the Polaris Innovation Fund. “65LAB”,...
View ArticleCyprotex launches "e-Store" for online ordering of ADME-Tox services
Evotec SE today announced the official launch of the Cyprotex “e-Store”, offering simplified online access to the company’s comprehensive range of ADME-Tox services.
View ArticleEvotec and Amplitude Ventures launch partnership for Pre-Amp
Evotec SE today announced a translational BRIDGE partnership with Pre-Amp, a new venture studio created by Amplitude Ventures, a full-stack venture capital firm focused on investing in precision...
View ArticleEvotec joins iCARE4CVD a consortium to personalise prevention and...
Evotec SE today announced its participation in iCARE4CVD, an international public-private research consortium iCARE4CVD (individualised care from early risk of cardiovascular disease to established...
View ArticleEvotec SE to announce results for the first nine months 2023 on 08 November 2023
Evotec SE will announce its financial results for the first nine months 2023 on Wednesday, 08 November 2023.
View ArticleEvotec and Dewpoint Therapeutics enter strategic partnership in oncology
Evotec SE and Dewpoint Therapeutics today announced a strategic R&D collaboration to advance Dewpoint’s leading oncology pipeline programmes of condensate modifying therapeutics (“c-mods”) to...
View ArticleEvotec receives SBTi approval for its near-term emissions reduction targets
Evotec SE today announced that the Company’s near-term emissions reduction targets have been approved by the Science Based Targets initiative (“SBTi”).
View Article